title: Zoladex as primary therapy in advanced prostatic cancer. A French cooperative trial.
abstract: From April 1984 to May 1986, 129 patients with prostate cancer entered a prospective trial with a new LH-RH agonist, Zoladex. Mean age was 72 years (range of 45-94 years) and, in most cases, patients had metastatic disease, not previously treated by chemotherapy or hormone therapy. Patients received a monthly injection of 3.6 mg. Serum testosterone was lowered into the range of castrate levels after 4 weeks of treatment. In 105 evaluable patients at 3 months, a 65% partial response (PR) rate was observed, with 11% stable and 24% progressive disease. Median time to progression was 37 weeks. Analysis of objective criteria revealed 30% PR for prostate volume and 51% CR-PR for prostatic acid phosphatases. Seventeen percent of lytic metastases had recalcified. One hundred twenty-nine patients were evaluable for toxicity. Endocrinological side effects were common: decrease in libido, 92%; impotence, 86%; hot flushes, 48%; and breast swelling or tenderness, 9%. Nonendocrinologic side effects were rare. The treatment is generally well accepted by patients owing to the convenient depot formulation and to the minor side effects.
authors.affiliation: Centre Alexis Vautrin, Nancy, France.
authors.forename: R
authors.initials: R
authors.lastname: Metz
authors.forename: M
authors.initials: M
authors.lastname: Namer
authors.forename: L
authors.initials: L
authors.lastname: Adenis
authors.forename: B
authors.initials: B
authors.lastname: Audhuy
authors.forename: R
authors.initials: R
authors.lastname: Bugat
authors.forename: P
authors.initials: P
authors.lastname: Colombel
authors.forename: J E
authors.initials: JE
authors.lastname: Couette
authors.forename: P
authors.initials: P
authors.lastname: Grise
authors.forename: R
authors.initials: R
authors.lastname: Khater
authors.forename: B
authors.initials: B
authors.lastname: LePorz
mesh_terms: D000135:Acid Phosphatase / Q000032:analysis; D000368:Aged; D000369:Aged, 80 and over; D002064:Buserelin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D005640:Follicle Stimulating Hormone / Q000097:blood; D005602:France; D017273:Goserelin; D006801:Humans; D007279:Injections, Subcutaneous; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009362:Neoplasm Metastasis; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy / Q000201:enzymology; D011446:Prospective Studies; D011467:Prostate / Q000201:enzymology; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000201:enzymology
chemical_list: D003692:Delayed-Action Preparations; D017273:Goserelin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D000135:Acid Phosphatase; D002064:Buserelin